2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1985

Cervical Spine Radiographs in Fibromyalgia Patients Show Reduced Cobb Angle and Suggest the Presence of Increased Muscle Pressure As a Cause of the Illness
Abstract Number: 189

Challenges and Opportunities of Implementing a Patient-Reported Measure of Physical Function through an Online Electronic Health Record Patient Portal in Routine Rheumatology Practice
Abstract Number: 330

Change in Bone Mineral Density in Patients with Rheumatoid Arthritis: Minimal 10-Year Follow-up
Abstract Number: 2538

Change in Self-Reported Health Status and Fatigue before and after the Diagnosis of Psoriatic Arthritis- the Nord-Trondelag Health Study (HUNT)
Abstract Number: 1558

Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis
Abstract Number: 1996

Changes in Cartilage Matrix Measured By MR T1ρ Are Correlated with Changes in Bone Erosion Volume Measured By HR-pQCT Three Months after MTX and Anti-TNF Treatment in Patients with Rheumatoid Arthritis: A Multi-Modality Imaging Study
Abstract Number: 1992

Changes in Clinical Disease Activity Are Associated with Changes in the Total MRI Inflammation Score in Rheumatoid Arthritis Patients Who Are Escalating Therapy in a Treat-to-Target (T2T) Regimen
Abstract Number: 2663

Changes in Disability over Time, and Their Relationship with Degree of Skin Thickening, in Patients with Limited and Diffuse Cutaneous Systemic Sclerosis: A Retrospective Cohort Study
Abstract Number: 1627

Changes in Heart Rate Variability Reflect Changes in Clinical Status and Patient Reported Outcomes in Systemic Lupus Erythematosus: A Longitudinal Analysis
Abstract Number: 884

Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients with Psoriatic Arthritis: An Integrated Analysis across Phase 3 and Long-Term Extension Studies
Abstract Number: 2537

Changes in Severity, Functional Status, and Wellbeing over Time Among Individuals with Ankylosing Spondylitis (AS) in Canada: Results from the RHUMADATA® Multicentre Registry
Abstract Number: 1467

Changes in the Immune Response of RA Patients Induced By 1 Year of Tocilizumab
Abstract Number: 2328

Characterisation of Lipid Mediator Profile and Immune Cells in Synovial Fluid of Juvenile Idiopathic Arthritis
Abstract Number: 2687

Characteristic of Pulmonary Arterial Hypertension in Patients with Anti-U1RNP Antibody-Positive-Connective Tissue Diseases Is Determined By the Underlying Disease Rather Than Autoantibody Profile
Abstract Number: 1309

Characteristics and Outcomes of Prospectively Reported Pregnancies Exposed to Certolizumab Pegol from a Safety Database

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].